MedTrace Logo

Early Detection of CMP in Patients With Breast Cancer Using Cardiac Magnetic Resonance

NCT04510532 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2023-06-01

No results posted yet for this study

Summary

Breast cancer is the most common cancers among women worldwide.Although chemotherapy and surgery have greatly improved the survival rate, most types of chemotherapy have been reported to have varying degrees of cardiotoxicity. The investigators will focus on the cardiotoxicity of pyrotinib and apatinib which belong to the new tyrosine kinase inhibitors in respective chemotherapy among more subjects.

Conditions

Interventions

DIAGNOSTIC_TEST

CMR examination

After recruiting participants and collecting the baseline information, a CMR scan and a post-processed imaging procedure will be carried on .And the follow-up is planned at 1,6 months after chemotherapy in order to detect the cardiac impairment

Sponsors & Collaborators

  • Ruijin Hospital

    collaborator OTHER

  • Shanghai Fifth People's Hospital

    collaborator UNKNOWN

  • RenJi Hospital

    lead OTHER

Principal Investigators

  • Meng Jiang, MD · RenJi Hospital, School of Medicine, Shanghai Jiantong University

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-10-30
Primary Completion
2023-09-30
Completion
2023-09-30

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04510532 on ClinicalTrials.gov